First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Clinical Trial ID NCT00322452

Rank	Title	Journal	Year	PubWeight™‹?›
1	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	N Engl J Med	2009	46.35
2	Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.	J Clin Oncol	2011	7.65
3	Lung cancer in never-smokers.	J Clin Pathol	2006	1.00
4	Lung cancer in the era of precision medicine.	Clin Cancer Res	2015	0.96
5	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).	Lung Cancer	2013	0.90
6	Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.	Asia Pac J Clin Oncol	2012	0.86
7	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.	Lung Cancer	2013	0.83